Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
braf v600e mutated marginal zone lymphoma may exhibit features that partially overlap with hairy cell leukemia
Original title: “BRAF V600E-mutated marginal zone lymphoma may exhibit features that partially overlap with hairy cell leukemia.”
treatment patterns in relapsed refractory marginal zone lymphoma real world evidence from seven countries
Original title: “Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries.”
The U.S. Food and Drug Administration today approved a new indication for Breyanzi (Lisocabtagene maraleucel) as the first Chimeric Antigen Receptor (CAR) T-cell therapy in the U.S.
Original title: “FDA Approves First CAR T-Cell Therapy for Marginal Zone Lymphoma In the US”